Roles of Prostaglandin E 2 in Cardiovascular Diseases Focus on the Potential Use of a Novel Selective EP 4 Receptor Agonist

Prostaglandin E2 (PGE2) is produced in inflammatory responses and regulates a variety of immunological reactions through 4 different receptor subtypes; EP1, 2, 3 and 4. However, the precise role of each receptor in cardiovascular disease has not yet been elucidated. Enhanced expression of some EPs has been observed in clinical and experimental cardiovascular diseases. EP agonists have been developed to clarify the role of each receptor. Recently, we developed a novel selective agonist to examine the effects of EP4 on cardiac transplantation, myocardial ischemia, and myocarditis. Of note, a selective EP4 agonist attenuated inflammatory cytokines and chemokines via attenuation of macrophage activation in inflammatory heart diseases. In this review article, we discuss the effects of PGE2 receptor agonists on the development of cardiovascular diseases. (Int Heart J 2011; 52: 266-269)

[1]  S. Narumiya,et al.  Prostaglandin E2 Induces Vascular Relaxation by E-Prostanoid 4 Receptor-Mediated Activation of Endothelial Nitric Oxide Synthase , 2007, Hypertension.

[2]  A. Rahmel,et al.  The Registry of the International Society for Heart and Lung Transplantation: twenty-seventh official adult heart transplant report--2010. , 2010, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[3]  M. Pfeffer,et al.  Ventricular Remodeling After Myocardial Infarction: Experimental Observations and Clinical Implications , 1990, Circulation.

[4]  M. Isobe,et al.  Pharmacological activation of the prostaglandin E2 receptor EP4 improves cardiac function after myocardial ischaemia/reperfusion injury. , 2009, Cardiovascular research.

[5]  G. Tufveson,et al.  Effects of prostaglandin E2 (PGE2) and drugs affecting PGE2 degradation on acute rejection of rat cardiac allografts. , 1992, Scandinavian journal of thoracic and cardiovascular surgery.

[6]  J. Meyer-Kirchrath,et al.  Cardiospecific Overexpression of the Prostaglandin EP3 Receptor Attenuates Ischemia-Induced Myocardial Injury , 2005, Circulation.

[7]  B. Koller,et al.  Receptors for prostaglandin E(2) that regulate cellular immune responses in the mouse. , 2001, The Journal of clinical investigation.

[8]  R. Phipps,et al.  Prostaglandins as modulators of immunity. , 2002, Trends in immunology.

[9]  X. Norel.  Prostanoid Receptors in the Human Vascular Wall , 2007, TheScientificWorldJournal.

[10]  S. Narumiya,et al.  Stress responses: the contribution of prostaglandin E2 and its receptors , 2011, Nature Reviews Endocrinology.

[11]  L. McCullough,et al.  Misoprostol, an anti-ulcer agent and PGE2 receptor agonist, protects against cerebral ischemia , 2008, Neuroscience Letters.

[12]  S. Narumiya,et al.  Prostanoid receptors: structures, properties, and functions. , 1999, Physiological reviews.

[13]  S. Narumiya,et al.  The role of prostaglandin E receptor subtypes (EP1, EP2, EP3, and EP4) in bone resorption: an analysis using specific agonists for the respective EPs. , 2000, Endocrinology.

[14]  S. Fazel,et al.  Microsomal Prostaglandin E2 Synthase-1 Deletion Leads to Adverse Left Ventricular Remodeling After Myocardial Infarction , 2008, Circulation.

[15]  E. Puré,et al.  Deletion of microsomal prostaglandin E synthase-1 augments prostacyclin and retards atherogenesis , 2006, Proceedings of the National Academy of Sciences.

[16]  S. Narumiya,et al.  Prostaglandin E(2)-EP(3) signaling suppresses skin inflammation in murine contact hypersensitivity. , 2009, The Journal of allergy and clinical immunology.

[17]  J. Meyer-Kirchrath,et al.  Reduction of infarct size by selective stimulation of prostaglandin EP(3)receptors in the reperfused ischemic pig heart. , 2000, Journal of molecular and cellular cardiology.

[18]  P. Collins,et al.  The prostaglandin analogs, misoprostol and SC-46275, potently inhibit cytokine release from activated human monocytes. , 1997, Immunopharmacology and immunotoxicology.

[19]  A. Pentland,et al.  The EP3 receptor stimulates ceramide and diacylglycerol release and inhibits growth of primary keratinocytes , 2005, Experimental dermatology.

[20]  R. Clark,et al.  Prostaglandin E2 inhibits in vitro and in vivo lymphocyte responses in allogeneic transplantation. , 1990, The Annals of thoracic surgery.

[21]  M. Matsuzaki,et al.  Nitric oxide contributes to the progression of myocardial damage in experimental autoimmune myocarditis in rats. , 1997, Circulation.

[22]  P. Libby,et al.  Prostaglandin E2 Suppresses Chemokine Production in Human Macrophages through the EP4 Receptor* , 2002, The Journal of Biological Chemistry.

[23]  M. Giembycz,et al.  Prostanoid receptor antagonists: development strategies and therapeutic applications , 2009, British journal of pharmacology.

[24]  S. Narumiya,et al.  Roles of prostaglandin E2-EP1 receptor signaling in regulation of gastric motor activity and emptying. , 2010, American journal of physiology. Gastrointestinal and liver physiology.

[25]  Daniel Henrion,et al.  Activation of prostaglandin E2 EP1 receptor increases arteriolar tone and blood pressure in mice with type 2 diabetes. , 2009, Cardiovascular research.

[26]  M. W. Flye,et al.  Intragraft delivery of 16, 16-dimethyl PGE2 induces donor-specific tolerance in rat cardiac allograft recipients. , 1991, Transplantation.

[27]  T. Kanda,et al.  Inhibition of cyclooxygenase-2 enhances myocardial damage in a mouse model of viral myocarditis. , 2005, Life sciences.

[28]  B. Koller,et al.  Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes. , 2001, The Journal of clinical investigation.

[29]  M. Isobe,et al.  The Anti-Inflammatory Mechanism of Prostaglandin E2 Receptor 4 Activation in Rat Experimental Autoimmune Myocarditis , 2011, Journal of cardiovascular pharmacology.

[30]  M. Isobe,et al.  The Mechanism of Anti-Inflammatory Effects of Prostaglandin E2 Receptor 4 Activation in Murine Cardiac Transplantation , 2009, Transplantation.

[31]  S. Narumiya,et al.  Emerging roles of prostanoids in T cell‐mediated immunity , 2010, IUBMB life.

[32]  S. Akira,et al.  Microsomal prostaglandin E synthase‐1 contributes to ischaemic excitotoxicity through prostaglandin E2 EP3 receptors , 2010, British journal of pharmacology.

[33]  S. Narumiya,et al.  International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. , 1994, Pharmacological reviews.

[34]  S. Doré,et al.  The PGE2 EP2 receptor and its selective activation are beneficial against ischemic stroke , 2010, Experimental & Translational Stroke Medicine.

[35]  M. Saito,et al.  Stimulation of prostanoid IP and EP(2) receptors dilates retinal arterioles and increases retinal and choroidal blood flow in rats. , 2007, European journal of pharmacology.

[36]  K. Takeuchi,et al.  Involvement of prostaglandin E receptor EP3 subtype in duodenal bicarbonate secretion in rats. , 2007, Life sciences.

[37]  L. Louedec,et al.  Vasorelaxation induced by prostaglandin E2 in human pulmonary vein: role of the EP4 receptor subtype , 2008, British journal of pharmacology.

[38]  J. Downey,et al.  Ischemic preconditioning: from adenosine receptor to KATP channel. , 2000, Annual review of physiology.

[39]  M. Southall,et al.  Prostaglandin Receptor Subtypes, EP3C and EP4, Mediate the Prostaglandin E2-induced cAMP Production and Sensitization of Sensory Neurons* , 2001, The Journal of Biological Chemistry.

[40]  T. Lanthorn,et al.  SC-46275: a potent and highly selective agonist at the EP3 receptor. , 1993, Prostaglandins, leukotrienes, and essential fatty acids.

[41]  V. Paralkar,et al.  Discovery of CP-533536: an EP2 receptor selective prostaglandin E2 (PGE2) agonist that induces local bone formation. , 2009, Bioorganic & medicinal chemistry letters.

[42]  R. DuBois,et al.  Fishing for prostanoids: deciphering the developmental functions of cyclooxygenase-derived prostaglandins. , 2006, Developmental biology.

[43]  S. Narumiya,et al.  Multiple signal transduction pathways through two prostaglandin E receptor EP3 subtype isoforms expressed in human uterus. , 2000, The Journal of clinical endocrinology and metabolism.

[44]  S. Narumiya,et al.  Roles of prostanoids in the pathogenesis of cardiovascular diseases: Novel insights from knockout mouse studies. , 2011, Pharmacology & therapeutics.

[45]  D. Aronoff,et al.  Prostaglandin E2 Inhibits Alveolar Macrophage Phagocytosis through an E-Prostanoid 2 Receptor-Mediated Increase in Intracellular Cyclic AMP12 , 2004, The Journal of Immunology.

[46]  T. Ichiyama,et al.  Enhancement of activated β1-integrin expression by prostaglandin E2 via EP receptors in isolated human coronary arterial endothelial cells: implication for the treatment of Kawasaki disease , 2009, Inflammation Research.

[47]  Y. Nakajima,et al.  Protective effect of prostaglandin E2 receptors EP2 and EP4 in alloimmune response in vivo. , 2006, Transplantation proceedings.

[48]  M. Kodama,et al.  Localization of porcine cardiac myosin epitopes that induce experimental autoimmune myocarditis. , 1995, Circulation research.

[49]  T. Yoshino,et al.  Effect of prostaglandin E2 on intercellular adhesion molecule-1 and B7 expression in mixed lymphocyte reaction1 , 2003, Transplantation.

[50]  H. Jabbour,et al.  Prostaglandin receptors are mediators of vascular function in endometrial pathologies , 2006, Molecular and Cellular Endocrinology.

[51]  R. Bolli.  The Late Phase of Preconditioning , 2000, Circulation research.

[52]  D. Woodward,et al.  Identification of 19 (R)-OH prostaglandin E2 as a selective prostanoid EP2-receptor agonist. , 1993, Prostaglandins.

[53]  A. Sakamoto,et al.  A PROSTAGLANDIN E2 RECEPTOR SUBTYPE EP4 AGONIST ATTENUATES CARDIOVASCULAR DEPRESSION IN ENDOTOXIN SHOCK BY INHIBITING INFLAMMATORY CYTOKINES AND NITRIC OXIDE PRODUCTION , 2004, Shock.